

Should remdesivir be used for COVID-19?

This write-up summarises a rapid evidence review of remdesivir as a potential treatment for patients with COVID-19. The information may be revised as new evidence emerges.

Background

Remdesivir is a novel nucleotide analog prodrug (broad spectrum antiviral). It was developed as a treatment for Ebola and Marburg virus infections, although when trialed in patients with Ebola virus it failed to show a survival benefit.¹ Remdesivir has subsequently shown reasonable antiviral activity against more distantly related viruses including MERS-coronavirus; therefore activity against other coronaviruses including SARS-CoV-2 infection is predicted.²⁻⁴ Review articles identified remdesivir as one of several possible treatments for COVID-19.⁵⁻⁷ Lu (2020) stated that remdesivir “may be the best potential drug for the treatment of [COVID-19]” given the drug had completed the clinical program for Ebola virus infection with relatively complete safety and pharmacokinetics data in humans.⁷

The Health Sciences Authority (HSA) in Singapore has issued a conditional registration for remdesivir to treat adults with COVID-19 who have an oxygen saturation $\leq 94\%$ or who require supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Prescription is restricted to infectious disease physicians and the manufacturer is required to submit further data in the future for HSA analysis.⁸ The US Food and Drug Administration (FDA) has issued emergency use authorisation for remdesivir to treat severe COVID-19 in hospitalised adults and children on the basis of initial data from two trials: NCT04280705 and NCT04292899.⁹ The European Medicines Agency (EMA) lists remdesivir as an investigational product for COVID-19¹⁰ and has recommended conditions for compassionate use in patients with COVID-19.^{11,12} Remdesivir has received exceptional approval in Japan, while other jurisdictions, such as Taiwan and South Korea have approved it for emergency use for patients with SARS-CoV-2 infection.^{13, 14, 15}

Clinical evidence

Clinical evidence for remdesivir to treat COVID-19 is limited, with initial results requiring confirmation and publication in peer reviewed journals:

- Preliminary results from a randomised controlled trial (RCT) of 1,063 patients hospitalised with COVID-19 (NCT04280705 or ACTT-1) revealed that the remdesivir group had a 31% faster time to recovery than the placebo group with a median time to recovery of 11 days (95% confidence interval [CI] 9 to 12) versus 15 days (95%CI 13 to 19) respectively ($p < 0.001$). Nearly 89% of the patients had severe disease at enrolment. Remdesivir was administered intravenously as a 200-mg loading dose on day 1, followed by a 100-mg daily maintenance dose on days 2 to 10 or until hospital discharge or death. Kaplan-Meier estimates for mortality at 14 days were not significantly different for remdesivir compared with placebo (7.1% vs 11.9%; hazard ratio [HR]: 0.70; 95% CI 0.47 to 1.04). Mortality rates at 28 days are pending as a large proportion of patients are yet to complete the trial. Changes in viral load were not measured. Serious adverse events (AEs) were reported in 21.1% of the remdesivir group and 27.0% of the placebo group. A subgroup analysis suggested that the recovery rate in Asian patients was lower compared with non-Asian patients; however, results are currently inconclusive as they are likely to be confounded by the small number of Asians in the trial and differences in baseline disease severity and clinical practices at the various clinical trial sites. The authors highlighted the need to start antiviral treatment before a patient requires mechanical ventilation and advised that an antiviral agent alone is unlikely to be sufficient given the high mortality rate in the remdesivir group.¹⁶
- An RCT (NCT04257656) in 237 adults with severe COVID-19 in China found no difference in the time to clinical improvement (on a six-point scale from death to hospital discharge) between remdesivir and placebo, and remdesivir did not result in a significant reduction in SARS-CoV-2 RNA load; however, the study was terminated before reaching the prespecified sample size

due to difficulty in recruitment. Adverse events were comparable between groups leading the authors to conclude that remdesivir was adequately tolerated.¹⁷

- A randomised, open label study of a five-day versus ten-day remdesivir regimen in 397 patients with severe COVID-19 (NCT04292899) found that both regimens achieved similar clinical improvement on the ordinal scale at 14 days (64% of patients in the five-day group and 54% in the ten-day group improved two points in status). No new safety signals were identified although the proportions of patients experiencing serious AEs and discontinuing treatment due to AEs were numerically higher in the ten-day group.¹⁸
- Published non-comparative studies and case reports have generally described improvement in clinical status in patients after initiation of remdesivir. Efficacy and mortality rates vary although the available data suggest that remdesivir may be more beneficial in patients with less severe disease, who do not require invasive ventilation or treatment in an intensive care unit. Serious AEs such as hypertransaminasemia, acute kidney injury, and multiple organ dysfunction syndrome, among others, were frequently observed.¹⁹⁻²³

Table 1: Registered RCTs for remdesivir in patients with COVID-19

Study identifier	Study Design	Intervention	Comparator	Date of primary completion
NCT04257656 ^{24, 17} [Terminated]	DB, SC [*] , phIII, RCT	Remdesivir	Placebo	May 2020
NCT04252664 ²⁵ [Suspended]	DB, SC [*] , phIII, RCT	Remdesivir	Placebo	April 2020
NCT04292899 ^{26, 18}	MC [†] , OL, phIII, RCT	Remdesivir (5 day regimen)	Remdesivir (10 day regimen)	Part A completed
NCT04292730 ^{27, 18}	MC [†] , OL, phIII, RCT	Remdesivir (5 day regimen)	Remdesivir (10 day regimen)	Part A May 2020
NCT04280705 ^{28, 16}	DB, MC [†] , phII, RCT	Remdesivir	Placebo	April 2020
NCT04315948 ²⁹	MC, OL, phIII, RCT	Remdesivir, lopinavir/ritonavir, lopinavir/ritonavir + interferon β -1A	Standard of care	March 2023
NCT04321616 ³⁰	MC, OL, phII/III, RCT	Remdesivir, hydroxychloroquine	Standard of care	August 2020
NCT04330690 ³¹	MC ^C , OL, phII, RCT	Remdesivir, lopinavir/ritonavir, hydroxychloroquine	Standard supportive care	March 2022
NCT04349410 ³²	phII/III, randomised trial	Remdesivir, hydroxychloroquine, azithromycin, doxycycline, primaquine, clindamycin, methylprednisolone, tocilizumab, interferon, losartan, convalescent serum	-	October 2020
NCT04410354 ³³	DB, MC, ** phII, RCT	Merimepodib + remdesivir	Remdesivir + placebo	July 2020
NCT04409262 ³⁴	DB, MC, ** phIII, RCT	Remdesivir + tocilizumab	Remdesivir + placebo	July 2020
NCT04401579 ³⁵	DB, MC, [†] phIII, RCT	Baricitinib + remdesivir	Remdesivir + placebo	August 2023
EudraCT 2020-000982-18 ³⁶	OL, MC, ^N phIII, RCT	Remdesivir, hydroxychloroquine	Standard of care	Not stated
EudraCT 2020-001784-88 ³⁷	OL, MC, ^F phIII, RCT	Remdesivir, hydroxychloroquine	Standard of care	Not stated
EudraCT 2020-001366-11 ³⁸	OL, MC, ^{S, Ir, I, P} phIV, RCT	Remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, interferon β -1A	Standard of care	Not stated
EudraCT 2020-000936-23 ³⁹	OL, MC, ^{‡, Au} phIII, RCT	Lopinavir/ritonavir, interferon β -1A, remdesivir, hydroxychloroquine	-	Not stated

Abbreviations: DB, double blind; MC, multicenter; OL, open label, phII, phase II; phIII, phase III; RCT, randomised controlled trial; SC, single centre. * China; ** USA † Study has sites in Singapore; ‡ France; ^C Canada; ^I Italy; ^{Cr} Croatia; ^N Norway; ^F Finland; ^S Spain; ^{Ir} Ireland; ^P Portugal; ^{Au} Austria

The World Health Organization (WHO) has begun conducting a large, global trial (SOLIDARITY)⁴⁰ on the most promising therapies identified to date to treat COVID-19, including remdesivir. Over 100 countries are currently included in the trial. The date of primary completion is March 2021, with findings expected to be reported by December 2021.

Recommendations from professional bodies

WHO recommends remdesivir (among other drugs) should not be administered as treatment or prophylaxis for COVID-19 outside of clinical trials.⁴¹

Locally, the Singapore National Centre for Infectious Diseases (NCID) notes there are no proven or licensed therapies for any coronavirus infection. However, in interim treatment guidelines for COVID-19, NCID suggests using remdesivir under a trial setting if possible and notes that timing of antiviral initiation may be important as administration after the peak viral titer is unlikely to reduce lung damage despite reducing viral loads.⁴²

COVID-19 treatment guidelines from the National Institutes of Health (NIH) in the USA recommend remdesivir for the treatment of COVID-19 in hospitalised patients with severe disease requiring supplemental oxygen. Remdesivir is not recommended for the treatment of mild or moderate COVID-19 outside of a clinical trial.⁴³

In guidelines for COVID-19 clinical management, the Italian National Institute for Infectious Diseases recommends remdesivir be administered to patients in critical condition and those with respiratory symptoms who are clinically unstable.⁴⁴

The seventh edition of the China National Health Commission (NHC) Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment does not specifically refer to remdesivir.⁴⁵

Conclusion

Preliminary RCT results showing a swifter recovery for patients with severe COVID-19 who received remdesivir compared with placebo must be weighed against the first published RCT in China that found no significant difference in time to clinical improvement or reduction in viral load. A limitation was the reduced power of the trial in China to detect a significant result as it was halted prematurely. Further mature clinical trial results are needed to build the evidence base for remdesivir. This will enable several outstanding issues to be addressed such as the impact of remdesivir on viral load, the patients who are most likely to benefit from treatment, and the efficacy and safety of remdesivir relative to other candidate therapeutics for COVID-19.

References

1. Mulangu S, Dodd LE, Davey RT, et al., (2019) A randomized controlled trial of Ebola virus disease therapeutics *N Engl J Med* 2019;381:2293-303.
2. Agostini ML, Andres EL, Denison MR et al., (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease *MBio* Mar-Apr; 9(2)
3. Sheahan TP, Sims AC, Baric RS et al., (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses *Sci Transl Med* June 28; 9(396)
4. Wang M, Cao R, Zhang L, et al., (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro *Cell Research* (2020) 30:269–271 Letter to the editor
5. Li H, Wang YM, Xu JY et al., (2020) [Potential antiviral therapeutics for 2019 novel coronavirus] *Chinese Journal of tuberculosis and respiratory diseases* Feb 5; 43(0)
6. Morse JS, Lalonde T, Xu S et al., (2020) Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV *ChemBioChem* 21; 730-738
7. Lu H (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV) *BioScience Trends*. 14(1):69-71.
8. Health Sciences Authority (HSA) of Singapore (2020) HSA grants conditional approval of remdesivir for treatment of COVID-19 infection. 10 June 2020. Accessed 10 June 2020 at: https://www.hsa.gov.sg/announcements/news/conditional_approval_remdesivir
9. Food and Drug Administration (FDA) of the United States of America (2020). Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. 1 May 2020. Accessed 2 May 2020 at: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment>
10. European Medicines Agency Press release 31 March 2020. Accessed 2 April 2020 at: www.ema.europa.eu/en/news/update-treatments-vaccines-against-covid-19-under-development

MOH-ACE COVID-19 RAPID REVIEW
Updated 10 June 2020. First published 24 March 2020.

11. European Medicines Agency. Press release 3 April 2020. Accessed 13 April 2020 at: <https://www.ema.europa.eu/en/news/ema-provides-recommendations-compassionate-use-remdesivir-covid-19>
12. European Medicines Agency. Summary on compassionate use. Remdesivir. 3 April 2020 EMA/178637/2020. Accessed 13 April 2020 at: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
13. Gilead (2020) Gilead announces approval of Veklury® (remdesivir) in Japan for patients with severe COVID-19. Press Release 7 May 2020. Accessed 20 May 2020 at: <https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gilead-announces-approval-of-veklury-remdesivir-in-japan-for-patients-with-severe-covid19>
14. Food and Drug Administration, Department of Health, Taiwan. (2020) Remdesivir for COVID-19. Accessed 9 June 2020 at: <https://www.fda.gov.tw/TC/newsContent.aspx?cid=4&id=1589566>
15. Reuters (2020) EU watchdog aims for speedy approval of remdesivir as COVID-19 treatment. 8 June. Accessed 9 June 2020 at: <https://www.reuters.com/article/us-health-coronavirus-gilead-ema/eu-watchdog-assessing-gilead-application-for-covid-19-treatment-idUSKBN23F1SM>
16. Beigel JH, Tomashek KM, Dodd LE, et al., (2020) Remdesivir for the treatment of COVID-19 - Preliminary Report. *N Eng J Med* May 22
17. Wang Y, Zhang D, Du G et al., (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet* April 29 2020
18. Goldman JD, Lye DCB, Hui DS, et al., (2020) Remdesivir for 5 or 10 days in patients with severe COVID-19. *N Engl J Med* May 27
19. Grein J, Ohmagari N, Shin D et al., (2020) Compassionate Use of Remdesivir for Patients with Severe Covid-19 *N Engl J Med* Apr 10
20. Antinori S, Cossu MV, Ridolfo AL, et al., (2020) Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status *Pharmacol Res.* May 11
21. Holshue ML, DeBolt C, Lindquist S et al., (2020) First case of 2019 novel coronavirus in the United States *N Engl J Med* 382: 929-936
22. Hillaker E, Belfer JJ, Bondici A et al., (2020) Delayed initiation of remdesivir in COVID-19 positive patient. *Pharmacotherapy* April 13
23. Durante-Mangoni E, Andini R, Bertolino L, et al., (2020) Early experience with remdesivir in SARS-CoV-2 pneumonia *Infection* May 16
24. Clinicaltrials.gov. Accessed 23 March 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04257656?term=remdesivir&draw=2&rank=1>
25. Clinicaltrials.gov. Accessed 23 March 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04252664?term=remdesivir&draw=2&rank=2>
26. Clinicaltrials.gov. Accessed 23 March 2020 at: <https://clinicaltrials.gov/ct2/show/record/NCT04292899?term=remdesivir&draw=2&rank=4>
27. Clinicaltrials.gov. Accessed 23 March 2020 at: <https://clinicaltrials.gov/ct2/show/record/NCT04292730?term=remdesivir&draw=2&rank=5>
28. Clinicaltrials.gov. Accessed 23 March 2020 at: <https://clinicaltrials.gov/ct2/show/record/NCT04280705?term=remdesivir&draw=2&rank=6>
29. Clinicaltrials.gov. Accessed 23 March 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04315948?term=Remdesivir&draw=2&rank=7>
30. Clinicaltrials.gov. Accessed 23 March 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04321616?term=remdesivir&draw=2&rank=8>
31. Clinicaltrials.gov. Accessed 30 April 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04330690?term=remdesivir&draw=2&rank=8>
32. Clinicaltrials.gov. Accessed 30 April 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04349410?term=remdesivir&draw=2&rank=20>
33. Clinicaltrials.gov. Accessed 9 June 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04410354?term=remdesivir&cond=COVID&draw=2&rank=2>
34. Clinicaltrials.gov. Accessed 9 June 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04409262?term=remdesivir&cond=COVID&draw=2&rank=6>
35. Clinicaltrials.gov. Accessed 9 June 2020 at: <https://clinicaltrials.gov/ct2/show/NCT04401579?term=remdesivir&cond=COVID&draw=2&rank=9>
36. Clinicaltrialsregister.eu. Accessed 21 May 2020 at: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000982-18/NO#P>
37. Clinicaltrialsregister.eu. Accessed 21 May 2020 at: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001784-88/FI>
38. Clinicaltrialsregister.eu. Accessed 21 May 2020 at: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001366-11/ES>
39. Clinicaltrialsregister.eu. Accessed 21 May 2020 at: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR>
40. <https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments>
41. World Health Organization (WHO) (2020) Clinical management of COVID-19. Interim Guidance. 27 May. Accessed 9 June 2020 at: <https://www.who.int/publications/i/item/clinical-management-of-covid-19>
42. National Centre for Infectious Diseases (NCID) Singapore. Interim treatment guidelines for COVID-19 (v1.0) 2 April 2020. Accessed 13 April 2020 at: <https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Documents/Treatment%20Guidelines%20for%20COVID-19%20%282%20Apr%202020%29%20-final.pdf>
43. National Institutes of Health (NIH). COVID-19 Treatment Guidelines. Accessed 30 March 2020 at: <https://www.covid19treatmentguidelines.nih.gov/introduction/>
44. Nicastrì E, Petrosillo N, Bartoli TA, et al., (2020) National Institute for Infectious Diseases "L. Spallanzani," IRCCS. Recommendations for COVID-19 clinical management. *Infectious Disease Reports* 2020; vol 12:8543
45. Chinese National Health Commission (NHC) Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment. Accessed 23 March 2020 at: <https://www.acc.org/latest-in-cardiology/articles/2020/03/17/11/22/chinese-clinical-guidance-for-covid-19-pneumonia-diagnosis-and-treatment>